Acalabrutinib
| CAS No. | 1420477-60-6 |
|---|---|
| MDL No. | MFCD29472294 |
| MF | C26H23N7O2 |
| MW | 465.50 |
| InChI Key | WDENQIQQYWYTPO-IBGZPJMESA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Acalabrutinib is an irreversible, second-generation Bruton's tyrosine kinase (BTK) inhibitor belonging to the imidazopyrazine class. It is substituted with 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3, and 8, respectively. Approved by the FDA, it is used for treating adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It functions as a non-specific protein-tyrosine kinase inhibitor, antineoplastic agent, and apoptosis inducer. It is a secondary carboxamide, benzamide, pyridine, aromatic amine, pyrrolidinecarboxamide, imidazopyrazine, ynone, and tertiary carboxamide.
| CAS No. | 1420477-60-6 |
|---|---|
| Product Name | Acalabrutinib |
Biological Targets
BTK
Associated Conditions
prolymphocytic leukemia·marginal zone B-cell lymphoma·follicular lymphoma·leukemia·chronic lymphocytic leukemia·
* The information provided here is compiled from public sources and is for reference only.